Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Increasing Skin Permeability to Improve Drug Delivery



Researchers from Shizuoka University in Japan have developed a method using atmospheric microplasma to disrupt this impermeable layer of the skin.

Share this!

November 22, 2016 | by Sarah Hand, M.Sc.

Transdermal drug delivery represents a promising way to administer active ingredients through the skin. Unfortunately, drug developers face considerable challenges when designing therapeutics that are able to pass through the tough outer layer of the skin, known as the stratum corneum.

While the stratum corneum protects the lower levels of skin cells from infection, it also prevents most drugs applied topically from passively diffusing into the blood stream. Now, researchers from Shizuoka University in Japan have developed a method using atmospheric microplasma to disrupt this impermeable layer.

Using conductive and non-conductive materials, the researchers tested the effects of the plasma treatment on the stratum corneum of pig skin. The results of their study were presented at the 63rd Annual Symposium and Exhibition of the American Vacuum Society (AVS).

When the researchers used a conductive material, the plasma jet caused significant damage to the skin samples. Conversely, the non-conductive material using atmospheric microplasma caused no damage to the skin.

This non-conductive microplasma treatment also increased the permeability of the skin, as demonstrated using a dye test. While skin is normally impermeable to dyes, the microplasma treatment allowed the dye to enter the skin through the stratum corneum, suggesting that the same results could be seen with drug products.

While the technique seems promising, the researchers will need to conduct further preclinical tests before microplasma can be used to improve transdermal drug delivery in humans. As skin is the largest organ in the human body, care will need to be taken to ensure that this technique does not permanently disrupt this important barrier.

Keywords: Skin, Drug Delivery, Preclinical


Share this with your colleagues!

Researchers Identify Role of ApoE4 Gene as Possible Drug Target in Alzheimer’s Disease

September 21, 2017 - A team of neurology researchers at Washington University School of Medicine in St. Louis have found that in the presence of the ApoE4 protein, another protein known as tau forms tangles in the brain which contributes to neuronal damage characteristic of Alzheimer’s disease.

Featured In: Life Science News

New Guidelines Address CAR-T Immunotherapy Toxicities to Prevent Patient Deaths

September 20, 2017 - Clinicians at The University of Texas MD Anderson Cancer Center have published new guidelines in the journal, Nature Reviews Clinical Oncology, which could help in the management of these toxicities.

Featured In: Biotech News, Drug Safety News

Microneedle Skin Patch Could Treat Common Metabolic Disorders

September 19, 2017 - Researchers at Columbia University Medical Center (CUMC) and the University of North Carolina have developed a microneedle skin patch impregnated with a drug capable of converting white fat into calorie-burning brown fat.

Featured In: Medical Device News


Five Reasons Why Toronto is Emerging as a Major Life Sciences Hub


Development and Manufacture of Highly Potent API Drug Products Throughout the Clinical Phases

Innovation through Integration – Providing Next Generation Biomedical Devices and Interconnects

Clinical Payments Case Studies: Improving Efficiency, Cash Management, and Compliance

Why Phase 3 Trials Fail: Oncology Case Studies and Lessons Learned

Copyright © 2016-2017 Honeycomb Worldwide Inc.